Deciphera Pharmaceuticals’ Investigational Drug Shows Encouraging Response Rates In Rare Type Of Cancer
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT)